These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
380 related articles for article (PubMed ID: 30138686)
1. Development of models estimating the risk of hepatocellular carcinoma after antiviral treatment for hepatitis C. Ioannou GN; Green PK; Beste LA; Mun EJ; Kerr KF; Berry K J Hepatol; 2018 Nov; 69(5):1088-1098. PubMed ID: 30138686 [TBL] [Abstract][Full Text] [Related]
2. Models estimating risk of hepatocellular carcinoma in patients with alcohol or NAFLD-related cirrhosis for risk stratification. Ioannou GN; Green P; Kerr KF; Berry K J Hepatol; 2019 Sep; 71(3):523-533. PubMed ID: 31145929 [TBL] [Abstract][Full Text] [Related]
3. Long-term effect of sustained virological response on hepatocellular carcinoma in patients with hepatitis C in Canada. Janjua NZ; Chong M; Kuo M; Woods R; Wong J; Yoshida EM; Sherman M; Butt ZA; Samji H; Cook D; Yu A; Alvarez M; Tyndall M; Krajden M J Hepatol; 2017 Mar; 66(3):504-513. PubMed ID: 27818234 [TBL] [Abstract][Full Text] [Related]
4. Prediction of Hepatocellular Carcinoma Development in Korean Patients after Hepatitis C Cure with Direct-Acting Antivirals. Hong H; Choi WM; Lee D; Shim JH; Kim KM; Lim YS; Lee HC; Choi J Gut Liver; 2024 Jan; 18(1):147-155. PubMed ID: 37076993 [TBL] [Abstract][Full Text] [Related]
5. Hepatocellular carcinoma risk decreases as time accrues following hepatitis C virus eradication. Vutien P; Kim NJ; Moon AM; Johnson KM; Berry K; Green PK; Ioannou GN Aliment Pharmacol Ther; 2024 Feb; 59(3):361-371. PubMed ID: 37955206 [TBL] [Abstract][Full Text] [Related]
6. Hepatocellular carcinoma occurs frequently and early after treatment in HCV genotype 3 infected persons treated with DAA regimens. Tayyab GUN; Rasool S; Nasir B; Rubi G; Abou-Samra AB; Butt AA BMC Gastroenterol; 2020 Apr; 20(1):93. PubMed ID: 32252635 [TBL] [Abstract][Full Text] [Related]
7. Cost Effectiveness of Hepatocellular Carcinoma Surveillance After a Sustained Virologic Response to Therapy in Patients With Hepatitis C Virus Infection and Advanced Fibrosis. Farhang Zangneh H; Wong WWL; Sander B; Bell CM; Mumtaz K; Kowgier M; van der Meer AJ; Cleary SP; Janssen HLA; Chan KKW; Feld JJ Clin Gastroenterol Hepatol; 2019 Aug; 17(9):1840-1849.e16. PubMed ID: 30580095 [TBL] [Abstract][Full Text] [Related]
8. Hepatocellular carcinoma decreases the chance of successful hepatitis C virus therapy with direct-acting antivirals. Prenner SB; VanWagner LB; Flamm SL; Salem R; Lewandowski RJ; Kulik L J Hepatol; 2017 Jun; 66(6):1173-1181. PubMed ID: 28161470 [TBL] [Abstract][Full Text] [Related]
9. Incidence of Hepatocellular Carcinoma After Direct Antiviral Therapy for HCV in Patients With Cirrhosis Included in Surveillance Programs. Nahon P; Layese R; Bourcier V; Cagnot C; Marcellin P; Guyader D; Pol S; Larrey D; De Lédinghen V; Ouzan D; Zoulim F; Roulot D; Tran A; Bronowicki JP; Zarski JP; Riachi G; Calès P; Péron JM; Alric L; Bourlière M; Mathurin P; Blanc JF; Abergel A; Serfaty L; Mallat A; Grangé JD; Attali P; Bacq Y; Wartelle C; Dao T; Thabut D; Pilette C; Silvain C; Christidis C; Nguyen-Khac E; Bernard-Chabert B; Zucman D; Di Martino V; Sutton A; Roudot-Thoraval F; Audureau E; Gastroenterology; 2018 Nov; 155(5):1436-1450.e6. PubMed ID: 30031138 [TBL] [Abstract][Full Text] [Related]
10. Low incidence of HCC in chronic hepatitis C patients with pretreatment liver stiffness measurements below 17.5 kilopascal who achieve SVR following DAAs. Søholm J; Hansen JF; Mössner B; Røge BT; Lauersen A; Hansen JB; Weis N; Barfod TS; Lunding S; Øvrehus A; Mohey R; Thielsen P; Christensen PB PLoS One; 2020; 15(12):e0243725. PubMed ID: 33301499 [TBL] [Abstract][Full Text] [Related]
11. Incidence of Hepatocellular Carcinoma in Patients With HCV-Associated Cirrhosis Treated With Direct-Acting Antiviral Agents. Calvaruso V; Cabibbo G; Cacciola I; Petta S; Madonia S; Bellia A; Tinè F; Distefano M; Licata A; Giannitrapani L; Prestileo T; Mazzola G; Di Rosolini MA; Larocca L; Bertino G; Digiacomo A; Benanti F; Guarneri L; Averna A; Iacobello C; Magro A; Scalisi I; Cartabellotta F; Savalli F; Barbara M; Davì A; Russello M; Scifo G; Squadrito G; Cammà C; Raimondo G; Craxì A; Di Marco V; Gastroenterology; 2018 Aug; 155(2):411-421.e4. PubMed ID: 29655836 [TBL] [Abstract][Full Text] [Related]
12. Dynamic noninvasive markers predict hepatocellular carcinoma in chronic hepatitis C patients without sustained virological response after interferon-based therapy: Prioritize who needs urgent direct-acting antiviral agents. Huang CM; Hu TH; Chang KC; Tseng PL; Lu SN; Chen CH; Wang JH; Lee CM; Tsai MC; Lin MT; Yen YH; Hung CH; Cho CL; Wu CK Medicine (Baltimore); 2017 Nov; 96(46):e8696. PubMed ID: 29145306 [TBL] [Abstract][Full Text] [Related]
13. Direct-acting antivirals after successful treatment of early hepatocellular carcinoma improve survival in HCV-cirrhotic patients. Cabibbo G; Celsa C; Calvaruso V; Petta S; Cacciola I; Cannavò MR; Madonia S; Rossi M; Magro B; Rini F; Distefano M; Larocca L; Prestileo T; Malizia G; Bertino G; Benanti F; Licata A; Scalisi I; Mazzola G; Di Rosolini MA; Alaimo G; Averna A; Cartabellotta F; Alessi N; Guastella S; Russello M; Scifo G; Squadrito G; Raimondo G; Trevisani F; Craxì A; Di Marco V; Cammà C; J Hepatol; 2019 Aug; 71(2):265-273. PubMed ID: 30959157 [TBL] [Abstract][Full Text] [Related]
14. Aspartate aminotransferase to platelet ratio index and sustained virologic response are associated with progression from hepatitis C associated liver cirrhosis to hepatocellular carcinoma after treatment with pegylated interferon plus ribavirin. Ng KJ; Tseng CW; Chang TT; Tzeng SJ; Hsieh YH; Hung TH; Huang HT; Wu SF; Tseng KC Clin Interv Aging; 2016; 11():1035-41. PubMed ID: 27536084 [TBL] [Abstract][Full Text] [Related]
15. Metformin reduces hepatocellular carcinoma incidence after successful antiviral therapy in patients with diabetes and chronic hepatitis C in Taiwan. Tsai PC; Kuo HT; Hung CH; Tseng KC; Lai HC; Peng CY; Wang JH; Chen JJ; Lee PL; Chien RN; Yang CC; Lo GH; Kao JH; Liu CJ; Liu CH; Yan SL; Bair MJ; Lin CY; Su WW; Chu CH; Chen CJ; Tung SY; Tai CM; Lin CW; Lo CC; Cheng PN; Chiu YC; Wang CC; Cheng JS; Tsai WL; Lin HC; Huang YH; Yeh ML; Huang CF; Hsieh MH; Huang JF; Dai CY; Chung WL; Chen CY; Yu ML; J Hepatol; 2023 Feb; 78(2):281-292. PubMed ID: 36208843 [TBL] [Abstract][Full Text] [Related]
16. Hepatocellular carcinoma risk assessment by the measurement of liver stiffness variations in HCV cirrhotics treated with direct acting antivirals. Ravaioli F; Conti F; Brillanti S; Andreone P; Mazzella G; Buonfiglioli F; Serio I; Verrucchi G; Bacchi Reggiani ML; Colli A; Marasco G; Colecchia A; Festi D Dig Liver Dis; 2018 Jun; 50(6):573-579. PubMed ID: 29567413 [TBL] [Abstract][Full Text] [Related]
17. Hepatocellular Carcinoma Incidences and Risk Factors in Hepatitis C Patients: Interferon versus Direct-Acting Agents. Kao YT; Liu YC; Cheng YT; Wen YW; Hsieh YC; Hsu CE; Su CW; Tai JC; Chen YC; Jeng WJ; Lin CY; Chien RN; Tai DI; Sheen IS Viruses; 2024 Sep; 16(9):. PubMed ID: 39339961 [TBL] [Abstract][Full Text] [Related]